DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Meckel syndrome, type 1 — screening already-approved drugs against its 5-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMeckel syndrome, type 1 maps to a 5-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for meckel syndrome, type 1 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
A 1997 family study described four persons with minor malformations related to Meckel syndrome, raising the possibility of manifesting heterozygotes. The authors stated it was uncertain whether these malformations represent partial expression of the disease or are coincidental, and noted that partial expression has been described in heterozygotes for other autosomal recessive diseases. They concluded that until the gene responsible for this lethal syndrome is cloned and sequenced, relatives of the proband may be offered genetic counselling and prenatal diagnosis.
A separate 1997 study excluded the P75 neurotrophin receptor (NGFR) gene as a candidate for Meckel syndrome. Sequence analysis of the coding region revealed one polymorphism but no potential disease mutation, and physical mapping showed the NGFR gene lies outside the MKS locus. The gene was investigated because of its role in embryonic development, its chromosomal location adjacent to the MKS locus, and Meckel-resembling findings in knock-out mice.
A 2014 paper, despite its title referring to jaw crusher vibration analysis, contains text identical to the 1997 family study and adds no new data on Meckel syndrome.
No drug, treatment, or intervention for Meckel syndrome is mentioned in any of these abstracts. What remains missing is the identification of the causative gene or genes, a molecular understanding of heterozygous expression, and any clinical trial or therapeutic strategy for this lethal autosomal recessive disease.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Medical Genetics · 1997 · 7 citations · open access
Associated malformations in the family of a patient with Meckel syndrome: heterozygous expression?
AbstractMeckel syndrome is an inherited autosomal recessive disease. A family is described in which four persons had minor malformations related to the syndrome, suggesting the possibility of manifesting heterozygotes. It is uncertain whether these malformations represent partial expression of the disease or are coincidental. However, partial expression has been described in heterozygotes for other autosomal recessive diseases. Until the gene responsible for this lethal syndrome is cloned and sequenced, such relatives of the proband may be offered genetic counselling and prenatal diagnosis.
Exclusion of the P75 neurotrophin receptor gene as a candidate gene for Meckel syndrome
AbstractNerve growth factor receptor p75 (NGFR) gene was investigated as a potential candidate gene in Meckel syndrome (MKS) because of its important role in embryonic development, chromosomal localization adjacent to the MKS locus and Meckel syndrome-resembling findings in knock-out mice phenotype. The sequence analysis of the coding region of the gene revealed one polymorphism but no potential disease mutation. Physical mapping of the critical chromosomal region finally showed that the NGFR gene lies outside the MKS locus.
Вестник Кузбасского государственного технического университета · 2014 · 0 citations
Специфика анализа виброакустических волн, генерируемых при работе щековых дробилок типа СМД
AbstractMeckel syndrome is an inherited autosomal recessive disease. A family is described in which four persons had minor malformations related to the syndrome, suggesting the possibility of manifesting heterozygotes. It is uncertain whether these malformations represent partial expression of the disease or are coincidental. However, partial expression has been described in heterozygotes for other autosomal recessive diseases. Until the gene responsible for this lethal syndrome is cloned and sequenced, such relatives of the proband may be offered genetic counselling and prenatal diagnosis.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
